Insomnia - Drug Pipeline Analysis and Market Forecasts to 2015

London, United Kingdom (PressExposure) December 22, 2009 -- GlobalData estimated the global insomnia market to be valued at $3.2 billion in 2008. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.8% for the next seven years to reach $3.6 billion by 2015. The growth will primarily be due to the increased prevalence of insomnia cases. Barriers for insomnia market are stronger in terms of both pricing (generics and me-too compounds in market) and volume barriers such as low treatment seeking rate, low diagnosis rate amongst others.

For further details on this report, please click or add the below link to your browser http://www.global-market-research-data.com/Report.aspx?ID=Insomnia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

GlobalData finds that the insomnia pipeline is strong. More than 34 products were in different developmental stages in 2008. Ciltyri, Silenor, Almorexant, Tasimelteon, Esmiratazepine and Indiplon in Phase III are the key products in pipeline. Ciltyri with features such as innovative mechanism of action (serotonin receptor antagonist) to target patients with frequent nocturnal awakening, remains the most keenly watched product in pipeline. Other features, such as no residual effect, no rebound effect and no sedative action, make it a promising molecule in insomnia space. The approval of this will make sanofi aventis a still more formidable player in the insomnia market. Companies like sanofi aventis, Somaxon Pharmaceuticals, GlaxoSmithKline, Vanda Pharmaceuticals Inc. and Merck with some of the most technologically advanced products in their pipeline portfolio, are expected to attract the most of investors’ attention. The global insomnia market has seen intense competition which is expected to further intensify in the coming years.

For further details on this report, please click or add the below link to your browser http://www.global-market-research-data.com/Report.aspx?ID=Insomnia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

GlobalData analyzed the current market landscape and found it to be strong. Current competition in the insomnia market is quite strong, thus acting as a barrier for new entrants. Competition in the insomnia market is driven not only by product characteristics such as efficacy and safety profile, but also by market characteristics such as number of competitors, pricing, cheap substitutes and generics, and treatment flow indicators such as patient compliance and physician perceptions. sanofi aventis, Sepracor Inc. and Takeda Pharmaceuticals remain the leading competitors in the global insomnia market. Together, these companies accounted for approximately 95% of the global market share in 2008. sanofi aventis remained the market leader with a share of approximately 70%. The global insomnia market has relatively smaller pockets of unmet needs compared to other markets.

GlobalData, the industry analysis specialist’s new report, “Insomnia – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global insomnia market. The report identifies the key trends shaping and driving the global insomnia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global insomnia sector.

For further details on this report, please click or add the below link to your browser http://www.global-market-research-data.com/Report.aspx?ID=Insomnia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

Or Visit our report store: http://www.globaldata.com/reportstore

About GlobalData

GlobalData is a global market intelligence services company providing information research and analysis products and services.

Press Release Source: http://PressExposure.com/PR/GlobalData.html

Press Release Submitted On: December 22, 2009 at 1:32 am
This article has been viewed 14889 time(s).